Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following Mohs micrographic surgery.

Background: There is a need to improve prognostic accuracy for patients with cutaneous melanoma. A 31-gene expression profile (31-GEP) test uses the molecular biology of primary tumors to identify individual patient metastatic risk.
Objective: Develop a nomogram incorporating 31-GEP with relevant clinical factors to improve prognostic accuracy.
Methods: In an IRB-approved study, 1124 patients from 9 Mohs micrographic surgery centers were prospectively enrolled, treated with Mohs micrographic surgery, and underwent 31-GEP testing. Data from 684 of those patients with at least 1-year follow-up or a metastatic event were included in nomogram development to predict metastatic risk.
Results: Logistic regression modeling of 31-GEP results and T stage provided the simplest nomogram with the lowest Bayesian information criteria score. Validation in an archival cohort (n = 901) demonstrated a significant linear correlation between observed and nomogram-predicted risk of metastasis. The resulting nomogram more accurately predicts the risk for cutaneous melanoma metastasis than T stage or 31-GEP alone.
Limitations: The patient population is representative of Mohs micrographic surgery centers. Sentinel lymph node biopsy was not performed for most patients and could not be used in the nomogram.
Conclusions: Integration of 31-GEP and T stage can gain clinically useful prognostic information from data obtained noninvasively.
Competing Interests: Conflicts of interest Drs Covington, Caruso, Quick, and Zolochevska are employees and stockholders at Castle Biosciences. Drs Thorpe, Bricca, Campoli, DeBloom, Fazio, Greenhaw, Kirkland, Machan, Brodland, and Zitelli have no conflicts of interest to disclose.
(Copyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)